What’s It About?  

With pivotal approvals and mounting investment in MASH, this Summit is your comprehensive guide to preclinical, translational, clinical and regulatory MASH drug development.   

The 8th MASH Drug Development Summit unites 120+ industry leaders to address the most pressing challenges in MASH and metabolic diseases. Harnessing FGF21s, THR-β Agonists, GLP-1 Agonists, FXR & PPAR Agonists to propel your MASH therapeutic pieplines. This is your opportunity to access cutting-edge R&D insights that can super-charge your end-to-end metabolic development strategy. 

Building on the momentum in the space from the recent FDA approval and GLP-1 blockbusters the 8th annual event will return to Boston this September 2024 to provide an update on the state of play and how to empower faster drug discovery and development.

Top 5 Takeaways

Delve into preclinical anti-fibrotic developments and their impact on ELF and PRO-C3 biomarkers and how to improve fibrosis replication with Novo Nordisk BMS, Pfizer and AstraZeneca

Accelerate your clinical trial design by optimizing cirrhosis, MASH and fibrosis targets in trials with AstraZeneca and 89Bios

Examine how GLP-1s can be leveraged in MASH to combat the disease drivers with Gilead, Altimmune and Seal Rock Therapeutics

Explore how the regulatory field is shifting and learn how to navigate regulatory approval with Madrigal and AstraZeneca

Leverage AI techniques and real world evidence to integrate data, harmonize predictions and identify future trends for MASH with Merck and AstraZeneca

Who Will You Meet?

Connect with senior biopharma leaders from Novo Nordisk, AstraZeneca, Pfizer, Gilead, BMS, Regeneron, Madrigal, 89Bio, Akero and more.

What Your Peers Have to Say


"The meeting was an excellent conference. It was a highly informative and interactive meeting. The speakers presented cutting edge approaches for novel treatments for obesity and NASH. There was plenty of time for discussions and networking CSO, Mitotherapeutix 


Networking with key opinion leaders and learning about pathbreaking science’’ Head of Systems Biology, Novo Nordisk 


Good selection of talks covering the latest data and trends in MASH and obesity. Good speakers. Small intimate setting, opportunities for networking’’ Senior Director, Paratus Sciences